Co-CEO Gerald Commissiong spoke with @Benzinga to discuss how DataMEDS AI is tracking GLP-1 outcomes and driving long-entrenched growth across our ecosystem. $MEDS #MEDS Read the full interview here: benzinga.com/news/health-car…

DataMeds AI, Inc. (@DataMEDSAI) (Nasdaq: $MEDS ) Interim Co-CEO Gerald Commissiong will present "What Patients Really Want" at the 2026 National Telehealth and Virtual Care Summit in Las Vegas on Monday, September 28, 2026 at 9:15 a.m. PT, the company announced September 25. The talk covers the growing desire among patients across the country to own their individual health data. DataMeds AI, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/datameds-ai-i… The Health Lives Here (@HealthLivesHere) mobile app incorporates the company's AI and blockchain platforms, while Corexa Health provides pharmacy services: • Health Lives Here is a campaign and mobile healthcare application that DataMeds AI is advancing together with NFL Alumni Health (@nflalumnihealth) • The Health Lives Here mobile application incorporates the company's artificial intelligence platform EinsteinRx™ and its blockchain-enabled smart contracts platform PharmacyChain™ • The company's Corexa Health (@corexahealth) subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health, LLC Regarding a summit that will unite healthcare leaders, clinicians, technology experts and policymakers, Gerald Commissiong, (@G_Commish) Interim Co-CEO of DataMeds AI, stated: "I look forward to showcasing our team’s work, outlining our vision of how patient ownership of their data will improve patient care while also reducing provider data access frustrations, and interacting with other leading healthcare providers to discuss how to improve healthcare access for those who need it." Read the full release: datamedsai.com/datameds-ai-t… DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Excited to announce that DataMeds AI will be presenting at the 2026 National Telehealth and Virtual Care Summit next week, sharing our vision for patient data ownership, reducing provider friction, and expanding care access. $MEDS #MEDS
 Read more: accessnewswire.com/newsroom/…

AI infrastructure is about more than powering AI applications. It can help accelerate innovation in areas that matter most, including cancer research. Chris explained how Axe Compute’s former cancer research division has transitioned to @DataMEDSAI, a company expert in using AI to advance innovation in cancer research. He then emphasized how greater access to AI compute is critical in helping researchers and organizations tackle complex problems, such as finding cures to diseases like cancer, as quickly as possible. Watch the full interview: piped.video/x42YMOubH9w #AxeCompute #AI #AIInfrastructure #CancerResearch

Following our acquisition of @AxeCompute’s Helmomics platform, we're proud to see this foundational work scaling the future of precision medicine. $MEDS Watch Axe Compute CEO Christopher Miglino on @FoxBusiness discussing AI in cancer research: foxbusiness.com/video/640554…

True health tech innovation starts with solving real problems, not chasing trends. $MEDS Read our Interim Co-CEO Gerald Commissiong’s latest feature in @CeoValiant: valiantceo.com/interviews/ge… (valiantceo.com/interviews/ge…)

DataMeds AI, Inc.(@DataMEDSAI) (Nasdaq: $MEDS ) launched its new corporate website, DataMedsAI.com, on September 21, 2026, with the redesigned site aligned to marketing initiatives now pending after two recently announced transactions. The launch follows the company's acquisition of Helomics Corporation's artificial intelligence cancer diagnostics lab from Axe Compute and the settlement of outstanding litigation tied to its 2023 acquisition of Wellgistics, LLC. DataMeds AI, Inc. is a B2i Digital (@b2idigital )Featured Company. See the company's in-depth profile at: b2idigital.com/datameds-ai-i… Both the Helomics closing and the litigation settlement preceded the launch, and Gerald E. Commissiong ties them to the planned Health Lives Here consumer application: • DataMeds acquired Helomics Corporation's artificial intelligence cancer diagnostics lab, a CLIA-certified laboratory, from Axe Compute • The litigation settlement extinguished approximately $19 million in liabilities from the company's balance sheet and retired 364,099 common shares • Interim Co-CEO Gerald E. Commissiong said the Helomics closing and the litigation settlement leave the company ready to launch the Health Lives Here consumer application as it begins telling the DataMeds story to the broader market Regarding the new site, Gerald E. Commissiong, Interim Co-CEO of DataMeds, stated: "Our new corporate website represents the parent company's new branding. We have retooled our marketing efforts to be AI-centric so that we are able to get organic traction online as we begin to draw earned media interest in our story. We intend to soft launch the Health Lives Here app in short order." Read the full release: datamedsai.com/datameds-ai-u… DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

DataMEDS AI’s digital evolution is complete! $MEDS #MEDS Explore our newly redesigned corporate website at datamedsai.com/ Read our full press release for more: accessnewswire.com/newsroom/…

@DataMEDSAI $MEDS at the new Helomics lab today. Extremely well outfitted to begin to drive volume for ChemoFX cancer assay for late stage cancers where there are few options, and where we can align to dispense the drugs from our Corexa Pharmacy and provide targeted nutritional support through some Tollo oncology products we are bringing online. Also, we will be expanding the test many to support patients that will be onboarded into our Health Lives Here app that we are preparing to soft launch on Apple and Android in short order Also, biggest ovarian cancer biobank in the world 28k+ samples matched with patient records. Lots of relationships to build our relationships with pharma. Very exciting time!

DataMEDS AI, Inc. (@DataMEDSAI (@Nasdaq : $MEDS ) has settled litigation tied to the May 2023 Wellgistics, LLC purchase agreement, extinguishing liabilities of approximately $19 million that had been carried on its balance sheet. The Tampa-based Health IT company pairs its EinsteinRx artificial intelligence platform and PharmacyChain smart contracts platform with pharmacy, pharmaceutical-adjacent and telemedicine business units. DataMEDS AI, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/datameds-ai-i… The consideration came in two parts, cash and retired shares, with the full terms in the company's SEC filing: • 364,099 shares of DataMEDS common stock were retired as part of the settlement agreement. • The company paid a total of $450,000 in cash for the settlement. • Additional terms are set out in a Form 8-K filed with the SEC and linked in the release. Regarding the company's focus following the settlement, Gerald E. Commissiong, (@G_Commish) Interim Co-CEO of DataMEDS, stated: "The Company is pleased to put this outstanding litigation behind it so it can focus on solving healthcare's biggest challenges for our clients through the vertical integration of healthcare delivery, and the compliant tokenization of pharmaceutical supply tracking and patient data." Read the full release: accessnewswire.com/newsroom/… DataMeds AI, Inc. (NASDAQ:MEDS) (formerly Wellgistics Health, Inc.) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health (@corexahealth) subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

$MEDS There is a lot more to this structurally. Given our very low share count (less than 4M) and even lower tradeable shares (less than 2M), we are looking to fulfill the promise of this $DVLT patent. nasdaq.com/press-release/dat…

DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked $MEDS #MEDS Read our full press release for complete details and disclosures: accessnewswire.com/newsroom/…

DataMEDS AI Completes $1.5 Million Helomics Acquisition, Expanding into Cancer Diagnostics investorshub.advfn.com/marke…

DataMeds AI’s acquisition of Helomics expands its reach into AI-driven cancer diagnostics, adding a CLIA/CAP-certified laboratory and CRO capabilities while broadening its healthcare technology platform. See DataMeds AI’s full Featured Company profile at: b2idigital.com/datameds-ai-i…

DataMeds AI, Inc. (@DataMEDSAI) (@Nasdaq : $MEDS) completed the acquisition of Helomics Corporation, the Pittsburgh-based artificial intelligence cancer diagnostics laboratory business of Axe Compute Inc. (Nasdaq: $AGPU). Helomics applies artificial intelligence to real-world tumor data to support drug discovery and cancer treatment decisions. DataMeds AI, Inc. is a B2i Digital (@b2idigital ) Featured Company. See the company's in-depth profile at: b2idigital.com/datameds-ai-i… The acquisition brings a certified laboratory, a contract research services business and operational capital to DataMeds: • Helomics acquired from Axe Compute in exchange for common shares and an acquisition note of DataMeds, for a total purchase value of $1.5 million • The Helomics CLIA/CAP-certified clinical laboratory, the Predictive Oncology CRO central lab services business and $1.5 million in cash • No third party debt requiring repayment and no outstanding, unpaid accounts payable outside of ongoing monthly operational expenses • Under DataMeds' ownership, Helomics is expected to expand beyond tumor molecular profiling and chemosensitivity testing into cancer screening and traditional CLIA laboratory services Regarding the expanded scope, Gerald Commissiong, Interim Co-CEO of DataMeds, stated: "Given Helomics' rich history of pioneering innovative solutions in the $40 billion U.S. cancer diagnostic and treatment solutions market, we intend to expand the scope of DataMEDS broader services with this acquisition beyond GLP-1 agonist side effects and Long COVID, into cancer diagnosis and treatment." Read the full release: accessnewswire.com/newsroom/… DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC (@TolloHealth). Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

DataMEDS AI interim Co-CEO Gerald Commissiong spoke with @WSJ on the massive challenge of pricing accurately in today’s volatile market. $MEDS #MEDS wsj.com/business/american-bu…

Today we announced the sale of Helomics, our Pittsburgh-based AI oncology business, to DataMEDS AI (NASDAQ: MEDS). With this step complete, our team, capital, and operations are dedicated entirely to one goal: meeting the accelerating demand for AI compute. We are fully committed to delivering best-in-class AI compute infrastructure, giving enterprises choice across hardware, geography, and deployment speed through Axe Compute Access and Axe Compute Build. Read the full announcement: investors.axecompute.com/new…

DataMEDS AI Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from @AxeCompute. $MEDS #MEDS Read our full press release for complete details and disclosures: accessnewswire.com/newsroom/…

$MEDS Together with @TolloHealth and @nflalumnihealth , the #HealthLivesHere campaign gets underway. #DataMedsAI Learn more about our partnership and how underserved rural communities are now empowered to take control of their health data: accessnewswire.com/newsroom/…

@DataMEDSAI Q2 revs up 14%. Intends drone delivery of orders. Popular weight loss treatment now available. Corexa subsidiary launches 2 new products. $70B market for muscle loss from glp weight loss products. Links below: